# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst William Plovanic maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from...
HC Wainwright & Co. analyst Yi Chen reiterates AngioDynamics (NASDAQ:ANGO) with a Buy and maintains $14 price target.
AngioDynamics reported a Q4 2024 adjusted EPS loss of $(0.05), beating the consensus of $(0.16). Sales rose 1.9% to $79.1 milli...